Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Amends Revolving Credit Facility, Enters Agreement for Term Loan Credit Facility

NEW YORK (GenomeWeb) – Laboratory Corporation of America has amended and restated an existing senior revolving credit facility in the principal amount of $1 billion and entered into a five-year term loan credit facility in the principal amount of $1 billion, it said in a recent filing with the US Securities and Exchange Commission.

The new five-year revolving credit facility provides LabCorp with the ability to increase the facility by up to $250 million on top of the $1 billion principal amount. It also provides for a subfacility of up to $100 million for swing line borrowings and a subfacility of up to $125 million for issuances of letters of credit.

Bank of America is the swing line lender and a letter of credit issuer, as well as the administrative agent for a group of financial institutions that are providing the revolving credit facility.

The new revolving credit facility can be used for general corporate purposes, including working capital, capital expenditures, the funding of share repurchases and other certain payments, acquisitions, and other investments.

The new facility amends and restates an existing credit facility agreed to in December 2011. As of Dec. 19, there were no outstanding borrowings under the new revolving credit facility, and existing letters of credit totaling $42 million were continued under the facility, LabCorp said.

Also, LabCorp has entered into a new term loan credit facility with Bank of America acting as the administrative agent. The facility can be used to pay all or part of LabCorp's $6.1 billion acquisition of Covance. If the deal is not completed by June 2, 2015, the commitments under the term loan credit facility will automatically terminate, LabCorp said in its SEC document. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.